Abstract
Objectives The Filtered Far-UVC (FFUV) handheld disinfection device is a small portable device that emits far UVC at 222nm. The objective of this study was to evaluate the device’s ability to kill microbial pathogens on hospital surfaces and compare it to manual disinfection using germicidal sodium hypochlorite wipes.
Methods A total of 344 observations (4 observations from 86 objects’ surfaces) were sampled with 2 paired samples per surface: a pre- and a post-sodium hypochlorite, and a pre- and a post-FFUV samples. The results were analyzed via a Bayesian multilevel negative binomial regression model. Additionally, the bacterial flora recovered were identified using mass spectrometry.
Results The estimated mean colony counts for the sodium hypochlorite control and treatment groups were 20.5 (11.7 – 36.0) and 0.1 (0.0 – 0.2) colony forming units (CFUs) respectively. The FFUV control and treatment groups had mean colony counts of 22.2 (12.5 – 40.1) and 4.1 (2.3 – 7.2) CFUs. The sodium hypochlorite samples had an estimated 99.4% (99.0% – 99.7%) reduction in colony counts, while those from the FFUV group had an 81.4% (76.2% − 85.7%) reduction.
Conclusions Our study demonstrated that FFUV handheld device effectively reduced microbial bioburden on surfaces in the healthcare setting. Several healthcare-associated infections (HAIs) causing pathogens (gram positive and negative bacteria) were retrieved from the pre-clean surfaces. The major benefit of FFUV is likely seen when manual disinfection is not possible or when supplementing cleaners or disinfectants with the low-level disinfection properties.
Competing Interest Statement
The funding support for the study was received from the Freestyle Partners, LLC, and its affiliate, FSP Innovations, LLC.
Funding Statement
This manuscript is the result of work supported with resources and the use of facilities at the Central Texas Veterans Health Care System, Temple, TX. The device and funding to conduct the study was provided by Freestyle Partners, LLC, and its affiliate, FSP Innovations, LLC to PC. The study sponsor did not have a role in the study design, data collection, data analysis, data interpretation, or writing of this manuscript. The corresponding author has full access to all the data in the study and had final responsibility for the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The revision includes updated discussion section.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
